Featured
August 14, 2026
In a commentary published in Bio-IT World, ASAP Managing Director Sonya Dumanis shares how Parkinson's disease diagnosis and treatment is shifting away from broad symptom management towards a precision medicine approach grounded in molecular profiling, novel biomarkers, and global data-sharing.
In July 2026, GP2 announced the 12th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PDRD. This release includes 21,156 additional genotyped participants and 25,046 additional whole genome sequencing (WGS) participants.
View Story
In this edition of the ASAP Research Round-Up, ASAP presents Q1 2026 highlights from across its portfolio, showcasing efforts to advance Parkinson’s discovery, facilitate the rapid global exchange of ideas, broaden open-science accessibility, and support the next generation of Parkinson’s researchers.
Read More
We are proud to share how we impacted the Parkinson’s disease research field in 2025. Read our report to see how the infrastructure and processes we established are changing the way science is done and are generating significant momentum.
Read More
Researchers have reached a major milestone in the effort to understand and treat Parkinson’s disease: more than 100,000 DNA samples from study participants around the world have now been genotyped and sequenced through the Global Parkinson’s Genetics Program (GP2).
Read More
GP2 announced its 11th data release at the end of 2025, bringing the total to over 100,000 samples from individuals worldwide, making it one of the most comprehensive and globally representative PD datasets to date.
Read More
In the third edition of the ASAP Research Round-Up, we share highlights from the past quarter across the ASAP portfolio that funnel new ideas into Parkinson’s disease (PD) research, facilitate the exchange of scientific ideas, expand access to resources for PD research, and support the next generation of Parkinson’s disease researchers.
Read More
ASAP’s Sonya Dumanis, PhD, and Andrew Singleton, PhD, joined The Genetics Podcast to discuss their recent publication in the American Journal of Human Genetics. In the episode, they emphasize the importance of increasing genetic diversity in Parkinson’s disease research and highlight GP2’s role in creating a scalable roadmap for building global research collaborations that can be adapted to other diseases and regions.
View Story
In this second edition of the ASAP Research Round-Up, ASAP shares advancements in Q2 2025 across the ASAP portfolio that fill critical knowledge gaps, promote rapid dissemination of scientific insights, expand resource accessibility, and support the next generation of Parkinson’s researchers.
Read More
In July 2025, GP2 announced the 10th data release on the Terra and the Verily® Workbench platforms in collaboration with AMP® PD. This release includes 11,109 additional genotyped participants and 13,339 additional WGS participants.
View Story
